TG Therapeutics Inc vs Zscaler Inc — how do they compare? TG Therapeutics Inc trades at $47.68 (market cap $7.58B), while Zscaler Inc trades at $187.47 (market cap $28.67B). The key difference: Zscaler Inc is far larger — about 3.8× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Zscaler Inc nearer its low. Which is the better fit depends on your goals.
| TGTX | ZS | |
|---|---|---|
Market Cap | $7.58B | $28.67B |
Sector | Health | Technology |
52-Week High | $59.06 | $336.27 |
52-Week Low | $26.94 | $118.05 |
Enterprise Value | $7.78B | $27.00B |
Trailing returns across standard periods
Latest headlines on both assets
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →